Hypertension as a Major Contributor to Chronic Kidney Disease and End‑Stage Renal Disease

Epidemiology and Population Impact

Hypertension accounts for roughly one‑third of all incident end‑stage renal disease (ESRD) cases in the United States, making it the second leading cause of ESRD after diabetes. (American Heart Association; American College of Cardiology) 1
Between 67 % and 92 % of individuals with chronic kidney disease (CKD) also have hypertension, with prevalence rising as kidney function declines. (American Heart Association) 1
In the 2012 U.S. data set, hypertension was the second‑most common assigned cause of ESRD, responsible for 34 % of new ESRD cases. (American Heart Association; American College of Cardiology) 1
Among U.S. adults with hypertension during 2009‑2012, about 15.8 % already met criteria for CKD (eGFR < 60 mL/min/1.73 m² or elevated albumin‑creatinine ratio). (American College of Cardiology) 2
In the Northern Manhattan Study, 36 % of cardiovascular events in Black participants were attributable to hypertension, underscoring a heightened risk in this population. (American College of Cardiology) 2

Approximately 71 % of U.S. adults with diagnosed diabetes also have hypertension. (American College of Cardiology) 2
In the Chronic Renal Insufficiency Cohort (CRIC), 86 % of participants were hypertensive. (American College of Cardiology) 2
Around 28.1 % of adults who have both hypertension and CKD exhibit apparent resistant hypertension, indicating a particularly high risk of disease progression. (American College of Cardiology) 2

CKD independently raises cardiovascular disease (CVD) risk; when combined with hypertension, the risk of adverse cardiovascular and cerebrovascular events rises markedly, especially in the presence of proteinuria. (American Heart Association) 1
Among hypertensive U.S. adults (2009‑2012), 41.7 % had a projected 10‑year coronary heart disease risk exceeding 20 %, reflecting a high absolute cardiovascular burden. (American College of Cardiology) 2

Masked hypertension is present in up to 30 % of CKD patients and is linked to accelerated CKD progression, highlighting the importance of out‑of‑office blood‑pressure monitoring. (American Heart Association) 1
Resistant hypertension affects roughly 28 % of individuals with concurrent hypertension and CKD, signifying more severe underlying pathophysiology and greater risk of renal decline. (American College of Cardiology) 2

Effective blood‑pressure control is a proven strategy to slow or prevent further decline in kidney function once CKD has developed. (American Heart Association) 1
Because of the tight interplay between hypertension and kidney disease, rigorous BP management is a critical therapeutic target for preventing progression to ESRD. (American Heart Association) 1

The American College of Cardiology and American Heart Association define hypertension in CKD as blood pressure ≥130/80 mmHg, which is the threshold for treatment initiation and target for blood pressure control 3, 4
All CKD patients with blood pressure ≥130/80 mmHg meet criteria for hypertension requiring treatment, regardless of CKD stage or presence of diabetes 3, 4
The definition applies uniformly across CKD stages 1-4, and the threshold is the same for patients with diabetic kidney disease or non-diabetic CKD 3, 4, 5

The SPRINT trial data shows that intensive blood pressure control reduces cardiovascular events and all-cause mortality in CKD patients, with CKD patients comprising 28% of participants 3, 4
CKD itself is an independent risk factor for cardiovascular disease, and coexisting hypertension and CKD substantially increases cardiovascular and cerebrovascular event risk 3, 4

Hypertension affects 67% to 92% of patients with CKD, with prevalence increasing as kidney function declines 3, 4
Masked hypertension occurs in up to 30% of CKD patients, making out-of-office blood pressure monitoring important in this population 3, 4
Standardized office blood pressure measurements, preferably using an automated device, are assumed in the definition, with a corresponding 24-hour ambulatory blood pressure monitoring goal of <125/75 mmHg 5